News Releases

News and information from The Leukemia & Lymphoma Society

Burlington Stores and LLS Bring Smiles to Those Touched by Blood Cancers

RYE BROOK, NY, September 12, 2018 – For 16 years, Burlington Stores has partnered with The Leukemia & Lymphoma Society (LLS), funding research and lifesaving treatments. Together, they have saved lives and helped bring smiles to those touched by blood cancers, with more than $32 million raised to date. However, with nearly 1.3 million people in the U.S. living with or in remission from blood cancers, there is s...

CANCER IS TOUGH, BUT LLS IS TOUGHER

View full release here.  Rye Brook, NY (August 28, 2018) – Contributing to nearly every advance in blood cancer research and treatment in decades, The Leukemia & Lymphoma Society (LLS) has invested more than $1.2 billion in cancer research, with groundbreaking results in immunotherapy, genomics and personalized medicine that are improving and saving lives of patients. These revolutionary new t...

LLS Renews Call for Strong Action to Ease the Soaring Cost of Cancer Care

View multimedia release here. Rye Brook, N.Y. (Aug. 7, 2018) — As costs for cancer care skyrocket – projected to be $173 billion by 2020, a 39 percent increase from 2010 – The Leukemia & Lymphoma Society® (LLS) is renewing its call for action to ease the cost of cancer care for patients. Today, LLS released a national “Progress Report on the Cost of Cancer Care,” a review of policy measures tak...

FDA Approval of New Precision Medicine Therapy for Deadly Blood Cancer

Rye Brook, N.Y. (July 20, 2018) – Progress in treating acute myeloid leukemia (AML), a blood cancer that takes more than 10,000 lives in the United States each year, took an important step forward today with the U.S. Food & Drug Administration (FDA) approval of ivosidenib (Tibsovo®) for patients who have a specific genetic mutation called IDH1. The Leukemia & Lymphoma Society (LLS), a leader i...

LLS Announces Board of Directors Appointments and New Chief Operating Officer

(Rye Brook, NY, July 10, 2018) - The Leukemia & Lymphoma Society (LLS) announced today five new appointments to its board of directors, including four influential research scientists; Casey Cunningham, M.D., Christopher Flowers, M.D., Janice L. Gabrilove, M.D. and Ruben A. Mesa, M.D. Their appointments build strength in the diagnosis and treatment of lymphoma and myeloproliferative neoplasms as well as methods fo...

Man and Woman of the Year Campaign Breaks Fundraising Records for Cures

View multimedia release here. Rye Brook, NY (July 9, 2018) – In a spirited philanthropic competition to raise the most money for cancer cures in a 10-week timeframe, dedicated community leaders and their teams of supporters in cities across the country volunteered their time, skills, energy and passion to compete for the prestigious national title of The Leukemia & Lymphoma Society’s (LLS) Man & W...

Bring Light to Someone Touched By Cancer on National Random Acts of Light Day

(Rye Brook, NY, June 12, 2018) – Despite the many advances in cancer treatments and survival rates, many patients still are living with cancer and experiencing the darkness that can come with it. That’s why The Leukemia & Lymphoma Society (LLS) conceived Random Acts of Light Day, in conjunction with its flagship fundraising campaign – Light The Night (LTN) (www.LightTheNight.org) – a series of 140 inspiri...

LLS Applauds Significant Approval for Leukemia Patients

Rye Brook, NY – June 11, 2018 – The U.S. Food and Drug Administration (FDA) decision to expand the approval of a targeted therapy for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) is a significant development in the treatment of these patients, according to The Leukemia & Lymphoma Society® (LLS). The FDA approved venetoclax (Venclexta®...

Pages

Media Contact

Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: